Table 1.
Variation of glycans determined by lectin microarray analysis of SP cells and MP cells
| No. | Lectin | Preferred glycan structure (terminal epitope) | SP1 ± SD | MP1 ± SD | SP1/MP1 | SP2 ± SD | MP2 ± SD | SP2/MP2 |
|---|---|---|---|---|---|---|---|---|
| 1 | LTL | Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc | 0.40 ± 0.02 | 0.40 ± 0.02 | 1.00 | 0.42 ± 0.02 | 0.45 ± 0.02 | 0.95 |
| 2 | PSA | Fuc α1-6GlcNAc, α-D-Glc, α-D-Man | 0.78 ± 0.01 | 0.79 ± 0.06 | 0.99 | 0.82 ± 0.04 | 0.88 ± 0.02 | 0.93 |
| 3 | LCA | Fuc α1-6GlcNAc, α-D-Glc, α-D-Man | 0.91 ± 0.07 | 0.84 ± 0.06 | 1.08 | 0.89 ± 0.01 | 0.89 ± 0.03 | 0.99 |
| 4 | UEA-I | Fuc α1-2(Gal β1-4)GlcNAc | 0.41 ± 0.02 | 0.53 ± 0.03 | 0.78** | 0.60 ± 0.02 | 0.61 ± 0.01 | 0.99 |
| 5 | AOL | Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc | 0.93 ± 0.34 | 0.65 ± 0.04 | 1.43 | 0.58 ± 0.04 | 0.55 ± 0.04 | 1.05 |
| 6 | AALª | Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex) | 1.22 ± 0.09 | 1.07 ± 0.04 | 1.14* | 0.95 ± 0.05 | 0.87 ± 0.01 | 1.10* |
| 7 | MALª | Sia α2-3Gal β1-4GlcNAc | 0.47 ± 0.02 | 0.60 ± 0.01 | 0.77*** | 0.63 ± 0.02 | 0.70 ± 0.01 | 0.90** |
| 8 | SNA | Sia α2-6Gal/GalNAc | 0.82 ± 0.02 | 1.01 ± 0.05 | 0.81** | 1.03 ± 0.03 | 0.90 ± 0.03 | 1.14** |
| 9 | SSA | Sia α2-6Gal/GalNAc | 0.75 ± 0.04 | 0.90 ± 0.06 | 0.84* | 1.03 ± 0.01 | 0.92 ± 0.01 | 1.11*** |
| 10 | TJA-I | Sia α2-6Gal/GalNAc | 1.65 ± 0.01 | 2.28 ± 0.08 | 0.73*** | 1.66 ± 0.15 | 1.56 ± 0.06 | 1.06 |
| 11 | PHA-L | Tri/Tetra-antennary complex-type N-glycan | 0.45 ± 0.03 | 0.45 ± 0.01 | 1.00 | 0.54 ± 0.01 | 0.59 ± 0.01 | 0.91** |
| 12 | ECA | Gal β1-4GlcNAc | 0.86 ± 0.04 | 0.93 ± 0.04 | 0.93 | 1.12 ± 0.04 | 1.18 ± 0.04 | 0.95 |
| 13 | RCA120 | Gal β1-4GlcNAc | 1.60 ± 0.07 | 2.43 ± 0.20 | 0.66** | 2.13 ± 0.08 | 2.25 ± 0.12 | 0.95 |
| 14 | PHA-E | Complex-type N-glycans with outer Gal and bisecting GlcNAc | 0.75 ± 0.05 | 1.33 ± 0.06 | 0.57*** | 1.01 ± 0.02 | 0.88 ± 0.05 | 1.15* |
| 15 | DSAª | (GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans | 1.75 ± 0.03 | 2.21 ± 0.06 | 0.79*** | 1.78 ± 0.04 | 2.04 ± 0.04 | 0.87** |
| 16 | GSL-II | Agalactosylated tri/tetra antennary glycans, GlcNAc | 0.48 ± 0.02 | 0.31 ± 0.00 | 1.52*** | 0.44 ± 0.02 | 0.43 ± 0.01 | 1.04 |
| 17 | NPA | High Man, Man α1-6Man | 1.52 ± 0.17 | 1.68 ± 0.03 | 0.90 | 1.41 ± 0.04 | 1.38 ± 0.07 | 1.02 |
| 18 | ConA | High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc) | 2.29 ± 0.23 | 2.23 ± 0.16 | 1.03 | 1.68 ± 0.11 | 1.59 ± 0.09 | 1.06 |
| 19 | GNA | High Man, Man α1-3Man | 0.98 ± 0.08 | 1.10 ± 0.01 | 0.89 | 1.02 ± 0.02 | 0.97 ± 0.03 | 1.05 |
| 20 | HHL | High Man, Man α1-3Man, Man α1-6Man | 0.67 ± 0.04 | 0.58 ± 0.01 | 1.17* | 0.75 ± 0.02 | 0.74 ± 0.03 | 1.01 |
| 21 | ACG | Sia α2-3Gal β1-4GlcNAc | 1.36 ± 0.18 | 1.59 ± 0.09 | 0.85 | 1.38 ± 0.07 | 1.57 ± 0.05 | 0.88* |
| 22 | TxLC-I | Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc | 1.06 ± 0.04 | 0.80 ± 0.05 | 1.32** | 0.97 ± 0.05 | 0.93 ± 0.04 | 1.04 |
| 23 | BPL | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc | 0.54 ± 0.05 | 0.53 ± 0.03 | 1.01 | 0.66 ± 0.02 | 0.63 ± 0.02 | 1.05 |
| 24 | TJA-II | Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals | 0.92 ± 0.04 | 1.01 ± 0.02 | 0.90* | 1.11 ± 0.06 | 1.12 ± 0.03 | 0.99 |
| 25 | EEL | Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc | 0.58 ± 0.04 | 0.33 ± 0.02 | 1.74** | 0.51 ± 0.02 | 0.52 ± 0.01 | 0.98 |
| 26 | ABAª | Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T | 2.16 ± 0.08 | 0.84 ± 0.06 | 2.58*** | 0.89 ± 0.01 | 0.84 ± 0.01 | 1.06* |
| 27 | LELª | (GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc) | 2.39 ± 0.12 | 2.75 ± 0.16 | 0.87* | 2.95 ± 0.08 | 3.16 ± 0.09 | 0.94* |
| 28 | STL | (GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone) | 1.77 ± 0.13 | 2.19 ± 0.14 | 0.81* | 2.21 ± 0.16 | 2.36 ± 0.09 | 0.94 |
| 29 | UDA | GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 | 1.65 ± 0.16 | 2.09 ± 0.32 | 0.79 | 1.62 ± 0.21 | 1.94 ± 0.26 | 0.84 |
| 30 | PWM | (GlcNAc α1-4)n | 0.52 ± 0.04 | 0.58 ± 0.08 | 0.90 | 0.82 ± 0.00 | 0.84 ± 0.03 | 0.98 |
| 31 | Jacalin | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) | 1.51 ± 0.25 | 1.55 ± 0.15 | 0.97 | 1.64 ± 0.04 | 1.60 ± 0.09 | 1.02 |
| 32 | PNAª | Gal β1-3GalNAc (α-Thr/Ser (T)) | 0.68 ± 0.09 | 0.36 ± 0.01 | 1.86** | 0.49 ± 0.01 | 0.43 ± 0.01 | 1.14** |
| 33 | WFA | Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc | 0.52 ± 0.05 | 0.51 ± 0.02 | 1.03 | 0.71 ± 0.08 | 0.66 ± 0.06 | 1.08 |
| 34 | ACA | Gal β1-3GalNAc (α-Thr/Ser (T)) | 2.20 ± 0.15 | 1.16 ± 0.14 | 1.90*** | 0.87 ± 0.07 | 0.97 ± 0.05 | 0.90 |
| 35 | MPA | Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) | 0.81 ± 0.08 | 0.50 ± 0.02 | 1.61** | 0.71 ± 0.04 | 0.66 ± 0.04 | 1.08 |
| 36 | HPA | α-Linked terminal GalNAc | 0.89 ± 0.04 | 0.43 ± 0.05 | 2.08*** | 0.45 ± 0.03 | 0.45 ± 0.02 | 1.01 |
| 37 | VVAª | α-linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal | 0.55 ± 0.03 | 0.44 ± 0.02 | 1.24** | 0.59 ± 0.03 | 0.43 ± 0.00 | 1.35*** |
| 38 | DBA | GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc | 0.41 ± 0.04 | 0.34 ± 0.01 | 1.21* | 0.46 ± 0.01 | 0.46 ± 0.01 | 1.00 |
| 39 | SBA | α or β-linked terminal GalNAc, GalNAc α1-3Gal | 0.56 ± 0.06 | 0.51 ± 0.05 | 1.10 | 0.78 ± 0.04 | 0.66 ± 0.02 | 1.18** |
| 40 | Calsepaª | High Man (Man2-6), N-glycans including bisecting GlcNAc | 0.79 ± 0.05 | 0.66 ± 0.02 | 1.21* | 0.80 ± 0.05 | 0.67 ± 0.02 | 1.20* |
| 41 | PTL-I | α-Linked terminal GalNAc | 0.48 ± 0.03 | 0.53 ± 0.05 | 0.92 | 0.59 ± 0.04 | 0.50 ± 0.02 | 1.17* |
| 42 | MAH | Sia α2-3Gal β1-3(Sia α2-6) GalNAc | 0.37 ± 0.03 | 0.49 ± 0.04 | 0.76* | 0.53 ± 0.02 | 0.50 ± 0.02 | 1.05 |
| 43 | WGAª | (GlcNAcβ1-4)n, NeuAc, multivalent Sia | 1.32 ± 0.09 | 1.52 ± 0.07 | 0.87* | 1.39 ± 0.02 | 1.48 ± 0.03 | 0.93** |
| 44 | GSL-IA4 | α-GalNAc (α-Thr/Ser (Tn)) | 0.53 ± 0.06 | 0.43 ± 0.03 | 1.22 | 0.70 ± 0.01 | 0.63 ± 0.02 | 1.11** |
| 45 | GSL-IB4ª | α-Gal | 0.75 ± 0.02 | 0.55 ± 0.03 | 1.35*** | 0.69 ± 0.01 | 0.62 ± 0.02 | 1.11** |
aSignificantly changed in two experiments; * p < 0.05; ** p < 0.01; *** p < 0.001